Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Britain Courts Anthropic Amid US Defense Department Dispute 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
OXNARD, Calif., Jan. 24, 2017 -- CURE Pharmaceutical (OTC Pink:CURR), a preeminent developer and manufacturer of advanced oral thin film for use in pharmaceutical, veterinary, and buccal and dermal over-the-counter applications, today announces it has up listed from the OTC Pink exchange to the OTC QB.
“We are pleased to have up listed our stock onto the OTC QB exchange,” said Rob Davidson, CEO of CURE Pharmaceutical. “We look forward to a continued productive relationship with OTC markets, and continuing to update our shareholders on our progress, both in terms of partnerships and corporate performance.”
About CURE Pharmaceutical
Headquartered in Oxnard, CA, CURE Pharmaceutical has developed and manufactures the most advanced oral thin film (CureFilm™) on the market today supported by its in-house, industry-leading full service cGMP manufacturing facility. CureFilm is more stable and durable than other oral thin films, with the ability to augment the dissolution for the intended rate of release through the buccal or gastrointestinal system. The technology enables differentiation within large therapeutic categories and potentially improves patient compliance, through its patented application of creating multiple layers, and sub-encapsulation of the delivered compound, potentially improving onset of action, lowering dosing, and enhancing efficacy, thereby widening the therapeutic index. CURE Pharmaceutical is traded under the symbol CURR. For more information about CURE Pharmaceutical, please visit its website at www.curepharmaceutical.com.
Forward-looking statements
This press release contains forward-looking statements, which are subject to a number of risks and uncertainties. All statements, other than statements of fact, including those statements with respect to the Company's business development, are forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.
Contact: Jules Abraham JQA Partners, Inc. 917-885-7378 [email protected]
